PLG and hyperinsulinemic hypoglycemia, familial, 4: Consistent with results of genetic elimination of plasminogen, Plg ASO‐treated mice displayed a significant reduction in metastatic lung lesions compared to control ASO‐treated mice (Fig. 2H), indicating that KPC2 metastatic potential is sensitive to both genetic plasminogen deficiency and pharmacologic plasminogen reduction.